Cardlytics Posts Mixed Q4 Results, Issues Cautious Outlook as Shares Decline
Shares of CARDLYTICS INC (NASDAQ:CDLX) moved lower in after-hours trading on Tuesday following the release of the company's fourth quarter and full-year 2025 financial results. The digital advertising platform reported a quarterly net loss that was wider than analysts had anticipated, while revenue came in slightly above expectations. However, a significantly weaker-than-expected forecast for the current quarter appears to be the primary driver behind the negative market reaction.
Earnings and Revenue Versus Estimates
For the critical fourth quarter, Cardlytics presented a mixed financial picture against Wall Street's benchmarks.
- Revenue: The company reported total revenue of $56.1 million, which surpassed the analyst consensus estimate of approximately $55.5 million.
- Earnings Per Share (EPS): Cardlytics reported a GAAP net loss of $0.15 per share. This result fell short of the estimated non-GAAP loss of $0.07 per share, indicating a wider loss than analysts had projected.
While the revenue beat is a positive note, the larger-than-expected loss seems to have tempered investor enthusiasm. The company's own non-GAAP metric, Adjusted Net Income, was $0.03 per diluted share, highlighting the significant impact of adjustments like stock-based compensation on its bottom line.
Key Takeaways from the Quarterly Report
The earnings release framed 2025 as a year of resetting the business. CEO Amit Gupta stated the company took steps to "improve our financial health" and is moving forward with "sharper focus and discipline." CFO David Evans emphasized a "focused, disciplined approach to execution and cost management in 2026."
A critical operational detail noted by management was the conclusion of campaigns with Bank of America in January, which is expected to lead to a decrease in Monthly Qualified Users (MQUs) going forward. Despite this headwind, MQUs grew 18.4% year-over-year in Q4 to 227.0 million. However, the key metric of Adjusted Contribution Per User (ACPU) fell 35% to $0.12, reflecting lower monetization efficiency.
Financially, the quarter showed some operational improvement on a cash basis. Net cash from operating activities increased to $13.0 million from $3.0 million a year ago, and Free Cash Flow turned positive at $10.5 million, compared to negative $1.5 million in Q4 2024.
A Cautious Outlook Drives Market Reaction
The most impactful element of the report was the company's guidance for the first quarter of 2026, which is substantially below current analyst expectations and explains the after-hours stock decline.
- Q1 2026 Revenue Guidance: Cardlytics anticipates revenue between $35.0 million and $40.0 million. This represents a projected year-over-year decline of 35% to 43% and is well below the analyst sales estimate of approximately $49.7 million for the quarter.
- Q1 2026 Billings Guidance: The company expects billings, a non-GAAP measure of gross customer spend, to be between $57.5 million and $63.5 million, indicating a 35% to 41% year-over-year drop.
This steep forecasted decline starkly contrasts with the full-year 2026 analyst sales estimate of $223.5 million. The guidance suggests the operational reset and the loss of the Bank of America campaigns will have a more severe near-term impact on the top line than the market had anticipated.
Market Performance and Path Forward
Following the earnings release, Cardlytics shares fell approximately 5.6% in after-market trading. This immediate reaction underscores investor concern over the magnitude of the projected slowdown in Q1. The company's strategy is now squarely focused on cost discipline and leveraging its core platform strengths with its remaining financial institution partners, including JPMorgan Chase and Wells Fargo.
For a detailed look at Cardlytics' historical earnings, future estimates, and full financial statements, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.